Biotech News
Related news
ERASErasca2026-07-13 20:01 EST
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST
Teva to Present at the Goldman Sachs Global Healthcare Conference
ZNTLZentalis2026-07-17 20:15 EST
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
LYELLyell Immunopharma2026-06-01 12:00 EST
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
GERNGeron2026-06-01 12:00 EST
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
KURAKura Oncology2026-07-14 11:02 EST
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
CMPXCompass Therapeutics2026-07-17 14:42 EST
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
REPLReplimune Group2026-05-31 12:00 EST
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
LYELLyell Immunopharma2026-06-25 12:00 EST
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct and pathway-level inhibition. ERAS-0015 ERAS-0015 is a RAS-targeted clinical candidate being evaluated in tumors...
Recent company news
ERASErasca2026-07-15 20:01 EST
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ERASErasca2026-07-14 03:10 EST
Erasca Announces Pricing of Upsized Public Offering of Common Stock
ERASErasca2026-07-13 20:19 EST
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
ERASErasca2026-07-13 20:01 EST
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
ERASErasca2026-05-27 12:00 EST
Erasca to Present at the Jefferies Global Healthcare Conference
Stock data
- Close
- 18.27 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States